Verici Dx (VRCI) Share Price, News & Analysis

Company Overview

Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection. The company is also developing Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Cardiff, the United Kingdom.

Key Stats

• Today's Range: 2.50 to 2.75
• 50-Day Range: 2.50 to 5.25
• 52-Week Range: 2.27 to 13
• Volume: 55,990 shs
• Average Volume: 335,038 shs
• Market Capitalization: £6.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VRCI Stock Analysis - Frequently Asked Questions

How have VRCI shares performed this year?

Verici Dx's stock was trading at GBX 9.75 at the beginning of the year. Since then, VRCI stock has decreased by 74.2% and is now trading at GBX 2.51.
View the best growth stocks for 2024 here.

How do I buy shares of Verici Dx?

Shares of VRCI stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Verici Dx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Verici Dx investors own include AutoZone (AZO), Intel (INTC), TJX Companies (TJX), Abacus Health Products (ABAHF), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM) and Bank of America (BAC).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: LON:VRCI
• CUSIP: N/A
• CIK: N/A
• Web: www.vericidx.com
• Phone: 44 207 9338780
• Fax: N/A
• Employees: 19
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-4,810,000.00
• Net Margins: -110.99%
• Pretax Margin: N/A
• Return on Equity: -58.12%
• Return on Assets: -26.14%

Debt

• Debt-to-Equity Ratio: 4.65
• Current Ratio: 4.54
• Quick Ratio: 8.49

Sales & Book Value

• Annual Sales: £4.33 million
• Price / Sales: 1.41
• Cash Flow: GBX 1.91 per share
• Price / Cash Flow: 1.31
• Book Value: GBX 4 per share
• Price / Book: 0.63

Miscellaneous

• Outstanding Shares: 242,540,000
• Free Float: N/A
• Market Cap: £6.10 million
• Optionable: Not Optionable
• Beta: 1.59